Cartesian's Descartes-08 Shows Durable Responses In Myasthenia Gravis
(RTTNews) - Tuesday, Cartesian Therapeutics (RNAC) reported additional retreatment data for investigational CAR-T therapy Descartes-08 showing sustained improvements in patients with generalized myasthenia gravis (MG).